Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Orders Label Revisions for Vyxeos, Inlyta, Imbruvica, and More Drugs
Japan’s Ministry of Health, Labor and Welfare (MHLW) on February 10 ordered safety-related label revisions for a range of medicines, including Nippon Shinyaku’s high-risk acute myeloid leukemia treatment Vyxeos (cytarabine + daunorubicin). For Vyxeos, the ministry instructed the addition of…
To read the full story
Related Article
- MHLW to Ease Uniform Driving Restrictions on Oral Antiepileptics
January 29, 2026
- Antivirals, Cancer Drugs Flagged in PMDA Risk Review
January 19, 2026
REGULATORY
- Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
- Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
- LDP, Ishin Seal Social Security Deal, Set Course for Chuikyo Reform
July 8, 2026
- LDP Lawmakers Renew Calls to Reflect Inflation in Drug Prices
July 8, 2026
- LDP’s New Diabetes Caucus to Push Patients’ Social Participation
July 8, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…